

A UNIFIED
APPROACH
**TO LUNG
CANCER CARE**

LungGPS™
Patient Management Platform



Medtronic
Further, Together

A NEED FOR BETTER NODULE MANAGEMENT

You've seen the desks covered in sticky notes. The complex spreadsheets. The handwritten notebooks. Today's nodule management is challenging at best. We're copying and pasting people's lives – if we're doing anything at all. And just like when we transcribe notes from one sheet to another, characters – people – are falling off and slipping through the cracks. This lack of coordinated infrastructure can impact survival.

What you need to know

Today, incidental nodules have a **25 percent malignancy rate**, compared to approximately just two percent within the screening population.^{1,2,3} Of those nodules, only 29 percent are followed and managed properly.⁴

And it's costly, too. Treating late-stage patients is **300 percent costlier** for hospitals and payers than it is for cancers caught at an earlier stage.⁵

BUT, WHAT IF?



This is a question we've asked ourselves over and over. It's how we push the limits of what technology can do in and for the body. It's how we made minimally invasive lung procedures the standard of care. And it's how we will continue to alleviate pain, restore health and extend life.

But what if we could do more? What if we could stop copying and pasting people's lives? What if we truly evolve the way we do business? Make the betterment of humanity as important as the bottom line? *Partner with the industry to help solve pulmonary care's biggest challenges?* In fact, what if the world's most important advancement in the human condition was us?

All of us - the global healthcare community - working together to make lung care better.

We will continue to make strides in technology. *But it will be the innovations we make working together as a community that will enable us to breakthrough and create the change we need.*

Together, we can transform lung care.

TEAMING UP TO MAKE A DIFFERENCE

It's this shared vision that's at the heart of our partnering with Philips. Together, we know we have the experience, reach, passion, and grit to transform lung cancer from a deadly disease to a managed condition where patients have what matters most — more quality time. To reach that goal, we combined our expertise and vision to create the LungGPS™ Patient Management Platform – a data management system designed to streamline the management of lung nodule patients, from identification through diagnosis, treatment, and long-term survivorship.

Backed by Philips' data software experience, and our lung care continuum and technology expertise, our joint effort provides solutions that focus on integrating hospital data, patient management, and clinical workflows.

The LungGPS™ platform is designed to make it easier for clinicians and their teams to identify and manage lung nodule patients within a complex healthcare system.

Medtronic
Further. Together

PHILIPS

WELCOME TO THE DAWN OF A NEW ERA IN LUNG NODULE CARE

The LungGPS™ platform is designed to:

- ***Automate and simplify*** the patient follow-up process and routine tasks
- ***Be your safety net*** by reducing opportunities for lost patient data
- ***Increase downstream patient volumes***, while decreasing the time to manage those patients⁶
- ***Create a consistent, guidelines-based framework*** to help you improve and standardize patient care

The LungGPS™ platform can help clinicians, nurse navigators, and healthcare IT professionals improve connected care and provide better patient management. The platform has a simple, closed-loop system enhanced by a powerful, automated Natural Language Processing (NLP) algorithm. This algorithm uses artificial intelligence to quickly search and analyze data across medical reports, highlighting relevant information that requires review and potentially follow-up. All of this lays the foundation for a more streamlined experience today, and a robust innovation plan for the future.

This is just the start. It's the dawn of a new era in lung nodule care. Join us.



REFERENCES

1. Tanner et al. Chest. 2015;148:1405.
2. MacMahon et al. Radiology. 2017;284:228.
3. Church et al. N Engl J Med 2013;368:1980-91.
4. Blagev, et al. J Am College of Radiology. 2014;11:378-383.
5. Gildea et al. ClinicoEconomics and Outcomes Research. 2017;9:261-269.
6. Data on file at Philips. Brown et al. J Natl Compr Canc Netw. 2016;14:181-4.



Medtronic

161 Cheshire Lane
Plymouth, MN 55441
USA
Tel: (763) 210-4000
Fax: (866) 706-5639
medtronicsolutions.medtronic.com/lung-health

medtronic.com

Medtronic and Medtronic with logo are U.S. and internationally registered trademarks of Medtronic AG. Other brands are trademarks of a Medtronic company.

DMK00908 Rev A © Medtronic, Inc.
2018 Plymouth, MN. All rights reserved.
05/2018

Together, we can transform lung care.

We will continue to make strides in technology. But it will be the innovations we make working together as a community that will enable us to breakthrough and create the change we need.

lung care better.

All of us - the global healthcare community - working together to make the world's most important advancement in the human condition was us? *Industry to help solve pulmonary care's biggest challenges?* In fact, what if betterment of humanity as important as the bottom line? *Partner with the people's lives?* What if we truly evolve the way we do business? Make the But what if we could do more? What if we could stop copying and pasting minimaly invasive lung procedures the standard of care. And it's how we the limits of what technology can do in and for the body. It's how we made This is a question we've asked ourselves over and over. It's how we push



BUT, WHAT IF?



REFERENCES

1. Tanner et al. Chest. 2015;148:1405.
2. MacMahon et al. Radiology. 2017;284:228.
3. Church et al. N Engl J Med. 2013;368:1980-91.
4. Blagev et al. J Am College of Radiology. 2014;11:378-383.
5. Gálea et al. ClinicoEconomics and Outcomes Research. 2017;9:261-269.
6. Data on file at Philips. Brown et al. J Natl Compr Canc Netw. 2016;14:181-4.

Medtronic

161 Cheshire Lane
Plymouth, MN 55441
USA
Tel: (763) 210-4000
Fax: (866) 706-5639
medtronic.com

Medtronic and Medtronic with logo are U.S. and internationally registered trademarks of Medtronic AG. Other brands are trademarks of a Medtronic company.
DMK00908 Rev A © Medtronic, Inc. 2018 Plymouth, MN. All rights reserved. Printed in USA. 05/2018

A UNIFIED APPROACH TO LUNG CANCER CARE

LungGPS™
Patient Management Platform



Medtronic
Further. Together

The LungGPS™ platform is designed to make it easier for clinicians and their teams to identify and manage lung nodule patients within a complex healthcare system.



It's this shared vision that's at the heart of our partnering with Philips. Together, we know we have the experience, reach, passion, and grit to transform lung cancer from a deadly disease to a managed condition where patients have what matters most — more quality time. To reach that goal, we combined our expertise and vision to create the LungGPS™ Patient Management Platform — a data management system designed to streamline the management of lung nodule patients, from identification through diagnosis, treatment, and long-term survivorship.

Backed by Philips' data software experience, and our lung care continuum and technology expertise, our joint effort provides solutions that focus on integrating hospital data, patient management, and clinical workflows.

TEAMING UP TO MAKE A DIFFERENCE

PHILIPS

A NEED FOR BETTER NODULE MANAGEMENT

You've seen the desks covered in sticky notes. The complex spreadsheets. The handwritten notebooks. Today's nodule management is challenging at best. We're copying and pasting people's lives – if we're doing anything at all. And just like when we transcribe notes from one sheet to another, characters – people – are falling off and slipping through the cracks. This lack of coordinated infrastructure can impact survival.

What you need to know

Today, incidental nodules have a **25 percent malignancy rate**, compared to approximately just two percent within the screening population.^{1,2,3} Of those nodules, only 29 percent are followed and managed properly.⁴

And it's costly, too. Treating late-stage patients is **300 percent costlier** for hospitals and payers than it is for cancers caught at an earlier stage.⁵

WELCOME TO THE DAWN OF A NEW ERA IN LUNG NODULE CARE

The LungGPS™ platform is designed to:

- **Automate and simplify** the patient follow-up process and routine tasks
- **Be your safety net** by reducing opportunities for lost patient data
- **Increase downstream patient volumes**, while decreasing the time to manage those patients⁶
- **Create a consistent, guidelines-based framework** to help you improve and standardize patient care

The LungGPS™ platform can help clinicians, nurse navigators, and healthcare IT professionals improve connected care and provide better patient management. The platform has a simple, closed-loop system enhanced by a powerful, automated Natural Language Processing (NLP) algorithm. This algorithm uses artificial intelligence to quickly search and analyze data across medical reports, highlighting relevant information that requires review and potentially follow-up. All of this lays the foundation for a more streamlined experience today, and a robust innovation plan for the future.

This is just the start. It's the dawn of a new era in lung nodule care. Join us.

Medtronic

Further, Together

